1-7 of 7
Karoline V. Gleixner, M.D.
Close
Sort by
Journal Articles

KIT D816V Mutation Burden Predicts Prognosis and Survival In Patients With Mastocytosis and Correlates With The WHO Type Of The Disease

Gregor Hoermann, M.D., Ph.D., Karoline V. Gleixner, M.D., Graziella E. Dinu, B.Sc., Georg Greiner, Friedrich Wimazal, M.D., Emir Hadzijusufovic, DVM, Gerlinde Mitterbauer, M.D., Christine Mannhalter, Ph.D., Peter Valent, Wolfgang R Sperr, M.D.
Journal: Blood
Blood (2013) 122 (21): 4052.
https://doi.org/10.1182/blood.V122.21.4052.4052
Published: 2013
Journal Articles

Small-Molecule Inhibition of BRD4 Is a Novel Promising Approach to Therapeutically Target Leukemia Stem Cells in AML,

Harald Herrmann, M.D., Katharina Blatt, M.Sc., Junwei Shi, Amy R. Rappaport, Karoline V. Gleixner, M.D., Sabine Cerny-Reiterer, D.V.M., Barbara Peter, D.V.M., Eric Wang, Wolfgang R. Sperr, M.D., James E. Bradner, MD, Scott W. Lowe, Ph.D., Christopher R. Vakoc, M.D., Ph.D., Johannes Zuber, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 3484.
https://doi.org/10.1182/blood.V118.21.3484.3484
Published: 2011
Journal Articles

Ponatinib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis,

Karoline V. Gleixner, M.D., Katharina Blatt, M.Sc., Barbara Peter, D.V.M., Emir Hadzijusufovic, DVM, Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 3497.
https://doi.org/10.1182/blood.V118.21.3497.3497
Published: 2011
Journal Articles

The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML

Karoline V. Gleixner, M.D., Harald Herrmann, M.D., Katharina Blatt, M.Sc., Winfried F Pickl, MD, Marina Konopleva, MD, PhD, Gahininath Y Bharate, Michael Andreeff, M.D., Ph.D., Hiroshi Maeda, MD, Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 4414.
https://doi.org/10.1182/blood.V118.21.4414.4414
Published: 2011
Journal Articles

BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.

Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Karoline V. Gleixner, M.D., Katharina Blatt, M.Sc., Susanne Herndlhofer, Hermine Agis, M.D., Werner Rabitsch, M.D., Berthold Streubel, M.D., Gerlinde Mitterbauer-Hohendanner, M.D., Wolfgang R. Sperr, M.D., Christian Sillaber, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2010) 116 (21): 3382.
https://doi.org/10.1182/blood.V116.21.3382.3382
Published: 2010
Journal Articles

Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFRα.

Christian Baumgartner, MD, Karoline V. Gleixner, M.D., Alexander Gruze, Puchit Samorapoompichit, M.D., Harald Esterbauer, M.D, Winfried F. Pickl, M.D, Christian Sillaber, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2007) 110 (11): 3559.
https://doi.org/10.1182/blood.V110.11.3559.3559
Published: 2007
Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

Veronika Ferenc, MD, Karoline V. Gleixner, M.D., Alexander Gruze, M.D., Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2007) 110 (11): 3554.
https://doi.org/10.1182/blood.V110.11.3554.3554
Published: 2007